Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

NCT02044822 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02044822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02044822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
August 6, 2014
Completion date
May 17, 2016
Enrollment
102 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia (cll) with 17p deletion